Key facts
- This page summarizes Thomas Ciulla's Form 4 filing for Clearside Biomedical, Inc. (CLSD).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Jan 2023, 15:32.
Thomas Ciulla - 20 Jan 2023 Form 4 Insider Report for Clearside Biomedical, Inc. (CLSD)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- CLSD
- Reported as of
- 20 Jan 2023
- Net transaction value
- -$20,139
- SEC form
- 4
- Accepted by SEC
- 20 Jan 2023, 15:32:01 UTC
- Prior SEC filing
- 11 Jan 2023
- Next SEC filing
- 12 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas Ciulla filed Form 4 for Clearside Biomedical, Inc. (CLSD) on 20 Jan 2023.
Change
- Previous filing in this sequence was filed on 11 Jan 2023.
- Current net transaction value: -$20,139.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLSD
transaction
Common Stock
Sale
- Transaction value
- $20,139
- Shares
- -13,700
- Change %
- -4.5%
- Price
- $1.47
- Shares after
- 291,890
- Date
- 20 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.45 to $1.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.